NRX Pharmaceuticals Inc. (NRXP)
NRXP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1719406/000143774926009418/0001437749-26-009418-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NRXP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001719406 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.2M |
| Net income | -$28.6M |
| Operating income | -$16.2M |
| Net margin | -2336.5% |
| Operating margin | -1324.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $7.8M |
| Total assets | $13.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 76.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As such, the Company has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements." | 10-Q 2026-08-14 |
| Cash and burn | $26.7M cash; operating cash flow -$4.9M a quarter. | Report 2026-06-30 |
| Shares outstanding | 43,295,767 (2026-08-14); 19,705,077 a year earlier; 81,700,918 three years earlier. 3y figure adjusted for split (1-for-10 overall). | Cover page 2026-08-14 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2024-04-02 | Source 2024-04-02 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-06-03 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-16 |
| Delisting | 25-NSE filed | 25-NSE 2026-05-22 |
| Auditor | Weinberg & Company, P.A., Los Angeles, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-11-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $1.1M | -$16.5M | -$8.9M | $26.7M | $412K | $3.4M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $1.1M | -$1.4M | -$4.3M | $6.7M | No debt tags | $2.3M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $983K | $360K | -$3.7M | $7.8M | $0 | $1.2M | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $242K | -$5.9M | -$2.9M | $7.2M | $10.1M | $242K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $0 | -$17.6M | -$4.0M | $2.9M | $10.2M | $0 | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $0 | -$5.5M | -$3.5M | $5.5M | $8.4M | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $0 | -$9.1M | -$2.1M | $1.4M | $1.6M | $0 | 10-K 2026-03-23 |
| Q3 2024 2024-09-30 | $0 | -$1.6M | -$2.3M | $1.6M | $3.7M | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2026-06-03 |
| Latest annual report FORM 10-K | 10-K | 2026-03-23 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-16 |
| Latest current report FORM 8-K | 8-K | 2026-11-02 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-11-05 |
Source: SEC EDGAR submissions feed, 480 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.0% |
| 1 month | -18.9% |
| 3 months | -34.4% |
| Year to date | -19.2% |
| 1 year | -15.4% |
| From 52-week high | -52.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EQ | Equillium Inc. | $1.15 | -10.85% | $94.7M |
| NBP | NovaBridge Biosciences | $0.7915 | -6.87% | $91.3M |
| RTSN | Retension Pharmaceuticals Inc. | $11.46 | -6.60% | $90.3M |
| PMVP | PMV Pharmaceuticals Inc. | $1.19 | -6.30% | $89.9M |
| ANIX | Anixa Biosciences Inc. | $2.55 | -2.67% | $88.6M |
| HURA | TuHURA Biosciences Inc. | $1.33 | -4.32% | $87.5M |
| KZIA | Kazia Therapeutics Limited | $5.60 | -15.41% | $87.1M |
| GNLX | Genelux Corporation | $1.92 | +2.95% | $86.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier